12,372 trials
Cervical Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants With Programmed…
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100
Chorea, Huntington
Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…
Burn Body Region Unspecified · Burn Shock
Primary: 24 Hour Average Urine Output (UOP) — 0.7; 1 ml/kg/hr
Alport Syndrome
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2) — 13.37 mL/min/1.73 m^2 — p=<0.0001
Posttraumatic Stress Disorder
Primary: Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5) — -23.69; -14.78 score on a scale
Wet Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read
COVID-19
Primary: Number of Participants With Sustained Recovery — 144; 136 Participants
Migraine
Primary: Long-term Safety of Chronic Intermittent Use of AXS-07 — 293; 118; 8; 10 Participants
Postoperative Pain · Obstetric Pain · Opioid Use
Primary: Visual Analog Pain Score — 3.5; 4.1; 5.2; 5.2 score on a scale — p=0.3
Breast Cancer
Primary: Change in Maximum Volumetric Breast Density Percentage — -0.038 Mean decrease in max VBD percentage
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema
Primary: Percentage of Injection Procedures With Successful Completions on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe…
Coronavirus · Covid19 · SARS-CoV-2
Primary: Number of Participants Who Experienced a Medically Attended Adverse Event (AE) Occurring in the Following 6 Months After Dose 2 — 95; 133; 58; 34 Participants
Respiratory Syncytial Virus Infections
Primary: Percentage of Participants Reporting Solicited Administration Site Events in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group — 53.6; 51.1; 34.4; 4.4…
Healthy Volunteers (Meningococcal Infection)
Primary: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) — 7; 2 Participants